Corbus Pharma Reports Director Changes & Financials
Ticker: CRBP · Form: 8-K · Filed: Apr 10, 2024 · CIK: 1595097
Sentiment: neutral
Topics: corporate-governance, officer-changes, financials
Related Tickers: CRBP
TL;DR
Corbus Pharma (CRBP) filed an 8-K detailing director changes, new officers, and financial statements.
AI Summary
Corbus Pharmaceuticals Holdings, Inc. filed an 8-K on April 10, 2024, reporting on the departure of directors, election of new directors, appointment of officers, and compensatory arrangements. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and headquartered in Norwood, Massachusetts.
Why It Matters
Changes in board composition and executive appointments can signal shifts in company strategy or governance, while the inclusion of financial statements provides insight into the company's current financial health.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not contain information that inherently increases risk.
Key Numbers
- 001-37348 — SEC File Number (Identifies the company's filing history with the SEC.)
- 46-4348039 — IRS Employer Identification No. (Company's tax identification number.)
- 20240410 — Report Date (Date of the earliest event reported in the 8-K.)
Key Players & Entities
- Corbus Pharmaceuticals Holdings, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- Norwood, Massachusetts (location) — Principal Executive Offices
- SAV Acquisition Corp (company) — Former Company Name
FAQ
What specific changes were made regarding directors and officers?
The 8-K filing indicates the departure of directors, the election of new directors, and the appointment of certain officers, along with details on their compensatory arrangements.
What is the primary business of Corbus Pharmaceuticals Holdings, Inc.?
Corbus Pharmaceuticals Holdings, Inc. is in the 'PHARMACEUTICAL PREPARATIONS' industry, as indicated by its Standard Industrial Classification code [2834].
When was the company formerly known as SAV Acquisition Corp?
The company's name was changed from SAV Acquisition Corp on December 20, 2013.
Where are Corbus Pharmaceuticals' principal executive offices located?
The principal executive offices are located at 500 River Ridge Drive, Norwood, Massachusetts, 02062.
What is the significance of the 'Financial Statements and Exhibits' item in this filing?
This item signifies that the filing includes important financial information and supporting documents that provide a deeper look into the company's financial performance and condition.
Filing Stats: 1,781 words · 7 min read · ~6 pages · Grade level 13.4 · Accepted 2024-04-10 16:58:13
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CRBP The Nasdaq Capital M
- $622,804 — d provides for an annual base salary of $622,804. In addition, Dr. Cohen is eligible to
- $463,455 — d provides for an annual base salary of $463,455. In addition, Mr. Moran is eligible to
Filing Documents
- crbp-20240409.htm (8-K) — 50KB
- crbp-ex10_1.htm (EX-10.1) — 208KB
- crbp-ex10_2.htm (EX-10.2) — 208KB
- 0000950170-24-043417.txt ( ) — 636KB
- crbp-20240409.xsd (EX-101.SCH) — 24KB
- crbp-20240409_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibit No. Description 10.1 Form of Fifth Amended and Restated Employment Agreement between Corbus Pharmaceuticals Holdings, Inc. and Yuval Cohen. 10.2 Form of Sixth Amended and Restated Employment Agreement between Corbus Pharmaceuticals Holdings, Inc. and Sean Moran. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Corbus Pharmaceuticals Holdings, Inc. Date: April 10, 2024 By: /s/ Yuval Cohen Name: Yuval Cohen Title: Chief Executive Officer